Last checked at 5 Apr 2024 13:40
Diaceutics PLC
BLOCK LISTING RETURN
Belfast and London, 5 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and bitech industry industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the the UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.
Name of applicant: | Diaceutics PLC | |||
Name of scheme: | UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards. | |||
Period of return: | From: | 6 October 2023 | To: | 6 April 2024 |
Balance under scheme from previous return: | 1,500,000 Ordinary Shares of £0.002 each | |||
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | N/A | |||
Number of securities issued/allotted under schemes during period: | 46,440 Ordinary Shares
| |||
Balance under scheme not yet issued/allotted at end of period | 1,453,560 Ordinary Shares | |||
Number and class of securities originally listed and the date of admission | 1,500,000 Ordinary Shares on 6 October 2023 | |||
Total number of securities in issue at the end of the period | 84,696,786 Ordinary Shares of £0.002 each | |||
Name of contact: | Nick Roberts | |||
Telephone number of contact: | As below | |||
Enquiries:
Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
Ryan Keeling, Chief Executive Officer | investorrelations@diaceutics.com |
Nick Roberts, Chief Financial Officer | |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland | |
Kate Hanshaw | |
Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almastrategic.com |
Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END